Amgen Doubles Down On AI, Genomic Investments In R&D

New Tech, R&D Heads ‘Joined At The Hip’

 
• By Mandy Jackson

David Reese, chief technology officer and former EVP of R&D, and newly appointed EVP of R&D Jay Bradner spoke with Scrip about how Amgen is pairing artificial intelligence with genomics plus data milestones in 2024.

Concept of artificial intelligence. Digital, communication, science, networks
Amgen is using artificial intelligence to search genomic data for new drug targets, among other uses • Source: Shutterstock

More from AI

More from Digital Technologies